Übersicht
This project will support Bavarian Nordic, a fully integrated Danish biotechnology company focused on the development, manufacturing and commercialisation of cancer immunotherapies and vaccines for infectious diseases. Financing is required for capital expenditure investments in Denmark.
The project supports the company's investments into a new fill-finish manufacturing facility. The investments cover the operational expenditure (OPEX) and capital expenditure (CAPEX) costs to construct, furnish and validate the new manufacturing facility to a commercial level. By co-investing in this project, the Bank contributes to fostering the generation of scientific knowledge and acumen within Europe, in addition to creating skilled employment opportunities.
The project falls under the annex II of the Environmental Impact Assessment (EIA) directive (2014/52/EU), referring to the manufacture of pharmaceutical products. The project has been screened by the competent authorities and there is no EIA required. Full environmental details will be assessed during the appraisal.
The promoter is a private company not operating in the utilities sector and is thus not covered by EU Directives on procurement.